Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sebelipase Alfa in Infants with Rapidly Progressive LAL-D
NCT02193867Phase 2Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jun 2014
- Primary completion
- Oct 2018
- Modality
- Replacement Enzymes
- Countries
- 4
01
Overview
A Phase 2 trial of sebelipase alfa in lysosomal acid lipase deficiency (LALD), sponsored by Alexion Pharmaceuticals. Started Jun 2014; status: terminated.
02
Drugs
sebelipase alfa
03
Conditions
lysosomal acid lipase deficiency (LALD)
Beyond the preview
Go deeper on NCT02193867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02193867.